Closed
The Marked Chart Wire · Business
Pfizer
Pfizer increased its 2026 revenue forecast to $62 billion to $64 billion and adjusted EPS to $2.95 to $3.05. The company also targets high single-digit revenue growth from 2028 to 2033.
Part of a series: Pfizer wins FDA approval and beats earnings estimates
Prices from Before the open · based on Tue close · Opens 9:30 AM ET. Each tile opens the stock's chart and news.
New to this? Read: Reading a stock chart
Pfizer
Pfizer reported third-quarter revenue of $16.58 billion and adjusted earnings per share of $0.87, both above estimates. The company raised its full-year revenue guidance to $62 billion to $64 billion and adjusted EPS to $2.95 to $3.05.
Pfizer
Pfizer is scheduled to release third-quarter results on November 3. Analysts currently project earnings per share of $0.73 and total revenue of $15.88 billion.
Novo Nordisk
Novo Nordisk reported quarterly earnings that exceeded expectations, driven by Wegovy pill sales that surpassed estimates. The company subsequently raised its full-year financial outlook.
CVS Split
CVS Health is said to be preparing to divide its operations into two separate publicly traded entities, according to a report.
L3Harris
L3Harris reported that missile program contracts increased its backlog by $11 billion during the quarter.
PFAS
3M agreed to a nine-year settlement covering up to 120,000 plaintiffs with PFAS-related injuries. The company will record a $5.8 billion pretax charge in the fourth quarter of 2026.
Fast headlines, summarized. Not verified and not advice. Check the full story before you act.